Meningiomas are known to be the most frequent intracranial neoplasms and account for approx. 25-33% of all intracranial tumours.Targeted radionuclide therapy with radiolabelled somatostatin analogues, also called Peptide Receptor Radionuclide Therapy (PRRT), has proven to be an effective treatment in metastatic intestinal neuroendocrine tumours and is currently used in advanced, recurrent or progressive meningiomas with promising results. In this study, the therapeutic index of a standard and newly developed radiolabelled somatostatin antagonist will be evaluated and compared in PRRT. In a second step, safety and efficacy of the latter will be assessed.

Start Date21 Apr 2021

Sponsor / Collaborator

Universitätsspital Basel

[+1]

NCT03773133

/ TerminatedPhase 1/2

A Multicentre, Open-Label Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

This study consists of two phases. The phase I study is designed to investigate the safety and tolerability of Satoreotide tetraxetan following fractionated i.v. administrations in pre-treated subjects with locally advanced or metastatic cancers expressing sstr2 as identified by Satoreotide trizoxetan Positron Emission Tomography (PET/CT) scans. This phase will encompass both radioactivity escalation and peptide mass dose evaluation. Phase II will assess the efficacy of Satoreotide tetraxetan in subjects in selected indications, in a basket design.

Start Date14 May 2019

Sponsor / Collaborator

Ipsen SA

NCT02592707

/ TerminatedPhase 1/2

An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors (NETs). The secondary objectives of this study were the assessment of biodistribution, dosimetry and preliminary efficacy of satoreotide tetraxetan.

Start Date06 Mar 2017

Sponsor / Collaborator

Ipsen SA

100 Clinical Results associated with 177Lu-Satoreotide tetraxetan

100 Translational Medicine associated with 177Lu-Satoreotide tetraxetan

100 Patents (Medical) associated with 177Lu-Satoreotide tetraxetan

Literatures (Medical) associated with 177Lu-Satoreotide tetraxetan

01 Jul 2024·European Journal of Nuclear Medicine and Molecular Imaging

Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours

Article

Author: Beauregard, Jean-Mathieu ; Navalkissoor, Shaunak ; Hicks, Rodney J ; Nicolas, Guillaume P ; McEwan, Alexander ; Lenzo, Nat P ; Volteau, Magali ; Eberlein, Uta ; Durand-Gasselin, Lucie ; Lassmann, Michael ; Schürrle, Seval Beykan ; Wild, Damian ; Ansquer, Catherine ; Haug, Alexander ; Grønbæk, Henning ; Pais, Ben

Abstract:

Purpose:

To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [177Lu]Lu-satoreotide tetraxetan in patients with advanced neuroendocrine tumours (NETs).

Methods:

This study was part of a phase I/II trial of [177Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three planned cycles (median activity/cycle: 4.5 GBq), in 40 patients with progressive NETs. Organ absorbed doses were monitored at each cycle using patient-specific dosimetry; the cumulative absorbed-dose limits were set at 23.0 Gy for the kidneys and 1.5 Gy for bone marrow. Absorbed dose coefficients (ADCs) were calculated using both patient-specific and model-based dosimetry for some patients.

Results:

In all evaluated organs, maximum [177Lu]Lu-satoreotide tetraxetan uptake was observed at the first imaging timepoint (4 h after injection), followed by an exponential decrease. Kidneys were the main route of elimination, with a cumulative excretion of 57–66% within 48 h following the first treatment cycle. At the first treatment cycle, [177Lu]Lu-satoreotide tetraxetan showed a median terminal blood half-life of 127 h and median ADCs of [177Lu]Lu-satoreotide tetraxetan were 5.0 Gy/GBq in tumours, 0.1 Gy/GBq in the bone marrow, 0.9 Gy/GBq in kidneys, 0.2 Gy/GBq in the liver and 0.8 Gy/GBq in the spleen. Using image-based dosimetry, the bone marrow and kidneys received median cumulative absorbed doses of 1.1 and 10.8 Gy, respectively, after three cycles.

Conclusion:

[177Lu]Lu-satoreotide tetraxetan showed a favourable dosimetry profile, with high and prolonged tumour uptake, supporting its acceptable safety profile and promising efficacy.

Trial registration:

NCT02592707. Registered October 30, 2015.

01 Dec 2023·European Journal of Nuclear Medicine and Molecular Imaging

A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

Article

Author: Navalkissoor, Shaunak ; Pennestri, Daniele ; Haug, Alexander ; Ansquer, Catherine ; Hicks, Rodney J ; Volteau, Magali ; Lenzo, Nat P ; Nicolas, Guillaume P ; Lassmann, Michael ; Grønbæk, Henning ; Wild, Damian ; Pais, Ben ; McEwan, Alexander ; Beauregard, Jean-Mathieu

Abstract:

Purpose:

We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [177Lu]Lu-satoreotide tetraxetan in 40 patients with previously treated, progressive neuroendocrine tumours (NETs), in which dosimetry was used to guide maximum administered activity.

Methods:

This study was conducted in two parts. Part A consisted of 15 patients who completed three cycles of [177Lu]Lu-satoreotide tetraxetan at a fixed administered activity and peptide amount per cycle (4.5 GBq/300 µg). Part B, which included 25 patients who received one to five cycles of [177Lu]Lu-satoreotide tetraxetan, evaluated different administered activities (4.5 or 6.0 GBq/cycle) and peptide amounts (300, 700, or 1300 μg/cycle), limited to a cumulative absorbed radiation dose of 23 Gy to the kidneys and 1.5 Gy to the bone marrow.

Results:

Median cumulative administered activity of [177Lu]Lu-satoreotide tetraxetan was 13.0 GBq over three cycles (13.1 GBq in part A and 12.9 GBq in part B). Overall, 17 (42.5%) patients experienced grade ≥ 3 treatment‑related adverse events; the most common were lymphopenia, thrombocytopenia, and neutropenia. No grade 3/4 nephrotoxicity was observed. Two patients developed myeloid neoplasms considered treatment related by the investigator. Disease control rate for part A and part B was 94.7% (95% confidence interval [CI]: 82.3–99.4), and overall response rate was 21.1% (95% CI: 9.6–37.3).

Conclusion:

[177Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three cycles, has an acceptable safety profile with a promising clinical response in patients with progressive, SSTR-positive NETs. A 5-year long-term follow-up study is ongoing.

Trial registration:

ClinicalTrials.gov, NCT02592707. Registered October 30, 2015.

30 Jun 2023·EJNMMI radiopharmacy and chemistry

First preclinical evaluation of [²²⁵Ac]Ac-DOTA-JR11 and comparison with [¹⁷⁷Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs.

Article

Author: Beekman, Savanne ; Bruchertseifer, Frank ; de Ridder, Corrina ; Denkova, Antonia ; Handula, Maryana ; Morgenstern, Alfred ; Konijnenberg, Mark ; de Blois, Erik ; Seimbille, Yann ; Stuurman, Debra

BACKGROUND:

The [¹⁷⁷Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostatin antagonist, [¹⁷⁷Lu]Lu-DOTA-JR11, that demonstrated better biodistribution profile and higher tumor uptake than [¹⁷⁷Lu]Lu-DOTA-TATE. Furthermore, treatment with alpha emitters showed improvement of the therapeutic index of PRRT due to the high LET offered by the alpha particles compared to beta emitters. Therefore, [²²⁵Ac]Ac-DOTA-JR11 can be a potential candidate to improve the treatment of NETs (Graphical abstract). DOTA-JR11 was radiolabeled with [²²⁵Ac]Ac(NO₃)₃ and [¹⁷⁷Lu]LuCl₃. Stability studies were performed in phosphate buffered saline (PBS) and mouse serum. In vitro competitive binding assay has been carried out in U2OS-SSTR2 + cells for ^natLa-DOTA-JR11, ^natLu-DOTA-JR11 and DOTA-JR11. Ex vivo biodistribution studies were performed in mice inoculated with H69 cells at 4, 24, 48 and 72 h after injection of [²²⁵Ac]Ac-DOTA-JR11. A blocking group was included to verify uptake specificity. Dosimetry of selected organs was determined for [²²⁵Ac]Ac-DOTA-JR11 and [¹⁷⁷Lu]Lu-DOTA-JR11.

RESULTS:

[²²⁵Ac]Ac-DOTA-JR11 has been successfully prepared and obtained in high radiochemical yield (RCY; 95%) and radiochemical purity (RCP; 94%). [²²⁵Ac]Ac-DOTA-JR11 showed reasonably good stability in PBS (77% intact radiopeptide at 24 h after incubation) and in mouse serum (~ 81% intact radiopeptide 24 h after incubation). [¹⁷⁷Lu]Lu-DOTA-JR11 demonstrated excellent stability in both media (> 93%) up to 24 h post incubation. Competitive binding assay revealed that complexation of DOTA-JR11 with ^natLa and ^natLu did not affect its binding affinity to SSTR2. Similar biodistribution profiles were observed for both radiopeptides, however, higher uptake was noticed in the kidneys, liver and bone for [²²⁵Ac]Ac-DOTA-JR11 than [¹⁷⁷Lu]Lu-DOTA-JR11.

CONCLUSION:

[²²⁵Ac]Ac-DOTA-JR11 showed a higher absorbed dose in the kidneys compared to [¹⁷⁷Lu]Lu-DOTA-JR11, which may limit further studies with this radiopeptide. However, several strategies can be explored to reduce nephrotoxicity and offer opportunities for future clinical investigations with [²²⁵Ac]Ac-DOTA-JR11.

News (Medical) associated with 177Lu-Satoreotide tetraxetan

06 Feb 2025

·www.prnewswire.com

U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics' Proprietary Radiopharmaceutical Cancer Therapy

225Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma Orphan Drug Designation follows outstanding preclinical data and FDA IND clearance Phase I/II human trials set to commence in Q1 2025 as a 'theranostic' targeted radionuclide treatment BERLIN, Feb. 6, 2025 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC). SCLC is a deadly condition that represents a significant unmet medical need due to the limited number of treatment options available to patients with this aggressive form of cancer. Two-thirds of SCLC patients are diagnosed at an advanced stage where the disease has already spread significantly, resulting in a poor prognosis and a 5-10% overall five-year survival rate. Ariceum will commence Phase I/II human clinical development of 225Ac-satoreotide under the trial name, SANTANA-225 in Q1 2025. Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: "Receiving ODD for 225Ac-satoreotide is a recognition of its potential as a treatment option for patients with SCLC and an important regulatory milestone for Ariceum. The FDA's ODD will support our objective to accelerate the development of 225Ac-satoreotide through human trials to provide a potentially life-saving therapy to patients with limited alternatives." The FDA provides ODD to drugs and biologics that demonstrate potential for the diagnosis and/or treatment of rare diseases or conditions that affect fewer than 200,000 people in the U.S. The designation provides development and commercial incentives for designated compounds and medicines, including eligibility for seven years of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, and an exemption from FDA user fees. In October 2024, Ariceum published outstanding preclinical data demonstrating the significant potential of 225Ac-satoreotide to outperform SSTR2 targeting agonists. 225Ac-satoreotide showed a high frequency of complete durable responses and 100% survival supporting advanced clinical development in SCLC, MCC, and other aggressive cancers. 225Ac-satoreotide in combination with its companion patient selection tracer 68Ga-SSO120 is being developed as a 'theranostic pair' for the combined diagnosis and targeted radionuclide treatment of multiple indications expressing SSTR2, such as SCLC, MCC, and other aggressive, hard-to-treat cancers. About Ariceum Therapeutics Ariceum Therapeutics is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of 'Marie Curie' whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum's lead targeted systemic radiopharmaceutical candidate, SSO110 ("satoreotide") labelled with Lutetium-177 (177Lu) and Actinium-255 (255Ac) is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in aggressive neuroendocrine tumours (NETs) such as small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC), all of which have limited treatment options and poor prognosis. Satoreotide is being developed as a 'theranostic pair' for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), currently in Phase 1 clinical development under the trial name CITADEL-123. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023. Ariceum Therapeutics, launched in 2021, acquired all rights to satoreotide from Ipsen, which has remained a shareholder of the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, the United Kingdom, and the United States. Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners, and Earlybird Venture Capital. For further information, please visit . SOURCE Ariceum Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1Orphan DrugAcquisitionOligonucleotide

16 Jan 2025

·endpts.com

Denmark’s new manufacturing learning center; Telix buys facility, assets and tech from ImaginAb

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Novo Nordisk is investing DKK 120 million ($16.5 million) into Denmark’s new manufacturing learning center called Campus Kalundborg, which is envisioned to grow the local student population to 1,500 by 2030. The Novo Nordisk Foundation is also investing DKK 202 million ($27.9 million) for teaching and training resources until 2031. In total, more than DKK 320 million ($44 million) is being invested. Telix Pharmaceuticals is acquiring a Californian research facility and its employees, a few early clinical-stage assets and biologics technology from antibody engineering company ImaginAb, according to a Monday release. No financial details were disclosed. Telix is also taking control of sales and marketing of its bone infection imaging asset, dubbed Scintimun, which it previously outlicensed to Curium Pharma, the company said Monday. Telix plans on researching Scintimun in combination with its Phase 2 bone marrow stem cell asset, called TLX66 (90Y-besilesomab). Curium will still manufacture Scintimun for Telix. Scintimun was EMA approved in January 2010. Charles River Laboratories is using Akron Bio’s line of liquid cytokines in its cell therapy manufacturing platform, the companies said Thursday. Cytiva and Cellular Origins are partnering to combine their cell therapy manufacturing platforms, according to a Thursday release. Isotope producer Nusano and Atley Solutions are partnering to establish a commercial supply chain for the radioisotope Astatine-211, the companies announced Thursday. ReciBioPharm, owned by CDMO Recipharm, has secured a three-year grant from the Bill & Melinda Gates Foundation to distribute its manufacturing tech to low and middle-income countries, the company said Monday. The technology is used to scale up manufacturing of RNA-based medicines. Emergent BioSolutions has received $16.7 million from the Center for the Biomedical Advanced Research and Development Authority (BARDA) to further develop and test its Zaire Ebola virus drug called Ebanga. This is its second contract option from BARDA; the original 10-year contract for Ebanga was signed in July 2023. Diagnostic solutions company Sysmex America is planning to build a new manufacturing and distribution facility in São José dos Pinhais, Brazil, the company said Wednesday. Construction is expected to start in the second quarter of 2025. Cell therapy CDMO BioCentriq is partnering with tech consultancy firm Orchestra Life Sciences, which will provide its manufacturing platform for BioCentriq’s new 60,000-square-foot Princeton, NJ facility. Orchestra will also help design the factory, according to a Tuesday release. CDMO Kindeva Drug Delivery and RNA vaccine tech company Emervax are collaborating to develop a new vaccine delivery method. Kindeva has given Emervax access to its microneedle vaccine patch, which Emervax will use with its RNA tech platform, according to a Jan. 9 press release. Alcami Corporation CEO Bill Humphries has stepped down and will be replaced by Patrick Walsh who will serve as interim CEO, the company said Monday. Walsh has previously acted as CEO of Alcami twice and has been chairman of the board for the past four years. International Isotopes is expanding its footprint by purchasing a 1.77-acre plot of land to build a 50,000-square-foot factory. Further, the company is leasing a new 8,600-square-foot building. ITM Isotope Technologies Munich is supplying the radioisotope Actinium-225 to Ariceum Therapeutics for its radiopharma pipeline, including its lead asset called satoreotide which is being investigated for certain cancers, according to the Monday release. Inhaler drugmaker Iconovo and Lonza are partnering to develop a spray-dried formula for Iconovo’s nasal device dubbed ICOone Nasal. Lonza will develop the formulation at its Bend, OR, factory, according to the Monday release.

VaccineCell TherapyDrug ApprovalPhase 2Executive Change

14 Jan 2025

·pipelinereview.com

FDA Clears Ariceum Therapeutics' 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma

BERLIN, Germany I January 14, 2025 I Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to commence a Phase I/II clinical trial (‘SANTANA-225’) of its proprietary radiolabelled peptide, 225 Ac-SSO110, in patients with small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC). The SANTANA-225 trial is a global, open-label Phase I/II study, that will assess the safety, tolerability, preliminary efficacy and recommended Phase II dose of 225 Ac-SSO110 in patients with extensive-stage SCLC or MCC who are on first-line maintenance therapy with checkpoint inhibitors. Ariceum is working with its partners and clinical sites in the US and other countries to commence recruitment of patients in Q1 2025. Germo Gericke, Chief Medical Officer at Ariceum Therapeutics, said: “This is an important milestone, not only for Ariceum but for the whole field of targeted radionuclide cancer treatments. 225 Ac-SSO110 is the first somatostatin receptor 2 (SSTR2) antagonist labelled with Actinium-225 to undergo human trials, providing the optimum combination of a long half-life α particle emitter with a long tumour retention tracer. Based on encouraging clinical data with 177 Lu-SSO110 and very promising pre-clinical data of 225 Ac-SSO110, we are very optimistic about the potential for patients with difficult to treat cancers.” 225 Ac-SSO110 is being developed together with its companion patient selection tracer 68 Ga-SSO120 as a ‘theranostic pair’ targeted radionuclide treatment of multiple indications expressing SSTR2, such as SCLC, MCC, and other aggressive cancers. Ariceum has recently expanded its global supply agreements for the medical radionuclides Actinium-225 ( 225 Ac) and Lutetium-177 ( 177 Lu), which will be used to radiolabel SSO110. About Ariceum Therapeutics Ariceum Therapeutics is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum’s lead targeted systemic radiopharmaceutical candidate, SSO110 (“satoreotide”) labelled with Lutetium-177 ( 177 Lu) and Actinium-255 ( 255 Ac) is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in aggressive neuroendocrine tumours (NETs) such as small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC), all of which have limited treatment options and poor prognosis. Satoreotide is being developed as a ‘theranostic pair’ for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), currently in Phase 1 clinical development under the trial name CITADEL-123. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023. Ariceum Therapeutics, launched in 2021, acquired all rights to satoreotide from Ipsen, which has remained a shareholder of the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, the United Kingdom, and the United States. Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners, and Earlybird Venture Capital. For further information, please visit www.ariceum-therapeutics.com . SOURCE: Ariceum Therapeutics

Phase 1AcquisitionOligonucleotide

100 Deals associated with 177Lu-Satoreotide tetraxetan

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16323

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Phase 2	United States	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	Austria	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	Belgium	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	France	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	Germany	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	Switzerland	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	United Kingdom	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	United States	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	Austria	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	Belgium	Ipsen SA	14 May 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02592707 (Pubmed \| Eur J Nucl Med Mol Imaging)	Phase 1/2	Neuroendocrine Tumors	40	[<sup>177</sup>Lu]Lu-satoreotide tetraxetan	flgpczzvdb(pbefxxlyrw) = cqdjjveyqq sgtjnmsywq (uukctrxjoe ) View more	-	26 Mar 2024
NCT02592707 (phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan, Pubmed \| Eur J Nucl Med Mol Imaging)	Phase 1/2	Somatostatin Receptor-Positive Neuroendocrine Tumor somatostatin receptor (SSTR)	40	[177Lu]Lu-satoreotide tetraxetan 4.5 GBq/300 µg	ioclbimyzz(pkzwoluqhn) = Two patients developed myeloid neoplasms considered treatment related by the investigator nuvgxvvouw (nftuquorfp ) View more	Positive	01 Dec 2023
NCT02592707 (phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan, CTgov)	Phase 1/2	Somatostatin Receptor-Positive Neuroendocrine Tumor	40	177Lu-IPN01072 (Part A: 177Lu-IPN01072 4.5 GBq)	vsmetlurss = lnvmqyxzun eqjpmnzwrx (qsutwzlxqz, ovvwdpygjb - bbzaxbhang) View more	-	19 Jul 2023
	Phase 1/2	Somatostatin Receptor-Positive Neuroendocrine Tumor	40	GBq+177Lu-IPN01072 (Part B Cohort 1: 177Lu-IPN01072 6 GBq)	vsmetlurss = wpbasmkkqg eqjpmnzwrx (qsutwzlxqz, tlekpuqqaa - ejhhuujllk) View more	-	19 Jul 2023
NCT02592707 (ESMO2020) Manual	Phase 1/2	Neuroendocrine Tumors	35	177Lu-satoreotide tetraxetan	sdtmsbvazv(aaulmbdefv) = 34.3%[lymphopenia/decrease in lymphocyte counts in 6 (17.1%), thrombocytopenia/decrease in platelets count in 5 (14.3%), neutropenia in 2 (5.7%) and anemia in 1 (2.9%)]. No grade 3/4 renal toxicities were reported. vytrqppwsq (dxlvbiydlv )	Positive	20 Sep 2020
NCT02609737 (Pubmed \| Clin Cancer Res) Manual	Phase 1	Neuroendocrine Tumors	20	Lutetium-177 DOTA satoreotide	ogmbzgwhtl(rzyscyoxdy) = raqiuopuve lmoqdiigrz (kepkupmtej ) View more	Positive	01 Dec 2019
SNMMI2016	Not Applicable	-	-	DOTA-JR11 (N.C.A 177Lu)	rtqrrwkzqx(tuwazmdfgw) = rsgfhipdpn njhkxxqnqd (ohgfuxqdnm )	-	24 May 2016
SNMMI2016	Not Applicable	-	-	DOTA-JR11 (177Lu/177mLu)	rtqrrwkzqx(tuwazmdfgw) = jrwohqazxd njhkxxqnqd (ohgfuxqdnm )	-	24 May 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis